Browse drugs

…rgoing percutaneous coronary intervention (PCI), ticagrelor and prasugrel are established potent P2Y12 inhibitors. Selection between thes…

…tment platelet reactivity to prasugrel, even after doubling the prasugrel dose. This case highlights rare resistance to newer P2Y12 inhib…

… P2Y12 receptor antagonist), mainly with low-dose prasugrel and ticagrelor. Off-label low-dose antiplatelet agents significantly reduced m…

…d and randomised to receive either 75 mg clopidogrel or 3.75 mg prasugrel daily. Patients were stratified based on estimated glomerular f…

…f using hydrophilic polymer-coated (HPC) flow diverters in with prasugrel single antiplatelet therapy to treat Posterior Circulation Aneu…

…treated IR injured hearts, especially DAPT with clopidogrel and ticagrelor. IR injury reduced ventricular perfusion and FCD neither of whi…

… that achieves faster, more consistent platelet inhibition than clopidogrel. Its use in the United States is limited by an U.S. Food and Dr…

…sing hydrophilic polymer-coated (HPC) flow diverters (FDs) with prasugrel single antiplatelet therapy (SAPT) to treat posterior circulati…

… regimens included ticagrelor (38.7%), clopidogrel (31.7%), and prasugrel (29.6%). At median 12-month follow-up, 97.8% of patients achiev…

…PT group and 6/62 (9.6%) in the DAPT group (p=0.431).Conclusion Prasugrel monotherapy for the treatment of distal IAs using the p48 MW HP…

…function], *17 [gain-of-function]) and VerifyNow PRU testing on clopidogrel. Thromboelastography with platelet mapping was available in 26.…

… (67.9%), clopidogrel (range 37.5-75 mg/day) in 33 (30.3%), and ticagrelor (range 90-180 mg/day) in 2 (1.8%) patients. Low-dose antiplatel…